OKYO Pharma Ltd (LON:OKYO; OKYO:LN), which is developing treatments for dry eye disease and chronic pain, has appointed one of America’s leading eye surgeons to head its scientific advisory board.
He is Dr A James Khodabakhsh, the medical director of the Beverly Hills Institute of Ophthalmology and chief of ophthalmology at the Cedars Sinai Medical Centre.
His remit is to bring together a small group of leaders in the field to “review and inform” the company’s plans to progress its lead product candidate, Chemerin, to the investigational new drug stage for dry-eye disease.
“This space has tremendous potential for growth and I truly feel we can add to it with our molecules,” Khodabakhsh said in a statement.
OKYO chairman Willy Simon said he was “honoured” to have the surgeon head up the scientific advisory team.
“We look forward to fully utilising his deep experience and clinical knowledge to assist in driving the development of Chemerin to its next stages of development," he added.
As well as roles at the Beverly Hills Institute and Cedars Sinai, Khodabakhsh is a clinical assistant professor of Ophthalmology at New York Medical Collge and managing partner of Specialty Surgical Centre.
He is also a consultant and speaker for Johnson and Johnson, Bausch and Lomb, Shire, Novartis, Sun Pharmaceuticals and Omeros.
Khodabakhsh has performed over 40,000 eye surgical procedures.